Sustained onabotulinumtoxinA Therapeutic Benefits in Patients With Chronic Migraine
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
To assess whether there is a sustained benefit and good safety with repeated
onabotulinumtoxinA sessions in chronic migraine over more than three years of treatment.
We prospectively enrolled 65 chronic migraine patients, who were classified as responders
after three sessions of onabotulinumtoxin A and were eligible to further continue treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Corfu Headache Clinic
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A onabotulinumtoxinA